GlassScriptPhysician profile
Jonathan Eaton
NPI 1780940320
$19,473.02
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $349 · 2021: $1,384 · 2022: $1,497 · 2023: $927 · 2024: $1,890 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,600 · Food and Beverage: $4,461 · Education: $4,400 · Travel and Lodging: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,600.00 |
| Food and Beverage | $4,460.75 |
| Education | $4,400.00 |
| Travel and Lodging | $422.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $11,529.36 | 2025 | Renal - Acute |
| Abiomed | $1,284.03 | 2020-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $1,023.84 | 2020-2025 | Fasenra, Lokelma, Tezspire |
| Actelion Pharmaceuticals US, INC. | $947.52 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $601.05 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Baxter Healthcare | $577.27 | 2021-2024 | Renal - Acute |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.71 | 2020-2025 | Ofev |
| Glaxosmithkline, LLC. | $492.04 | 2020-2025 | Nucala |
| Insmed, INC. | $407.67 | 2020-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $374.73 | 2019-2024 | Xarelto |
| Abbott Laboratories | $252.56 | 2019 | |
| Alexion Pharmaceuticals, INC. | $184.47 | 2021-2025 | Ultomiris, Soliris |
| Takeda Pharmaceuticals U.S.A., INC. | $181.69 | 2023-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $137.33 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $115.01 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $109.27 | 2021 | |
| Grifols USA, LLC | $98.89 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $77.44 | 2024-2025 | Giapreza, Zevtera |
| Pfizer INC. | $76.38 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.68 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $70.53 | 2024-2025 | Terlivaz, Acthar |
| Gilead Sciences, INC. | $70.38 | 2019-2021 | |
| Inspire Medical Systems, INC. | $57.97 | 2025 | Inspire |
| Dexcom, INC. | $38.74 | 2024 | Dexcom G6 Transmitter |
| Genzyme Corporation | $36.77 | 2025 | |
| Pinnacle Biologics, INC | $27.53 | 2024 | Photofrin |
| Genentech USA, INC. | $26.22 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.00 | 2025 | Lupkynis |
| Paratek Pharmaceuticals, INC. | $17.34 | 2024 | Nuzyra |
| Shionogi INC | $16.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Eaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.